Clora’s Post

ImmunoBlue, a promising biotech company founded by researchers, Elizabeth (Lizie) Sweeney and Rohan Fernandes, recently secured a Phase I STTR Award from the National Cancer Institute (NCI). ImmunoBlue’s groundbreaking work builds on extensive research conducted in collaboration with GWU on GW licensed technology, "T cells targeted against multiple antigens for cancer treatment," co-invented by Sweeney and Fernandes. This innovative approach aims to enhance treatment efficacy by tailoring T cell therapies to the unique characteristics of each patient’s tumor. The Phase I STTR Award from the NCI will enable ImmunoBlue to further demonstrate the feasibility of their personalized T cell product, paving the way for future clinical applications. We congratulate ImmunoBlue for this significant achievement and are excited about the potential impact of their work on the future of cancer treatment. Read more about the proposal here: https://lnkd.in/e5ZhvB_z. #GWU #TCO #Innovation #Biotech #CancerResearch #PersonalizedMedicine #Startup #NCI #Glioblastoma

💡Did you know chemotherapy is only effective in 20% of early-stage breast cancer patients? Yet, many undergo treatment, facing harsh side effects without clear benefits.   Introducing OncoFREE by DCGen – a groundbreaking breast cancer prognostic test that uses Next Generation Sequencing (NGS) technology to predict if cancer may spread.   OncoFREE analyzes RNA expression of 179 genes in tumor tissues to give a personalized risk assessment for cancer metastasis and recurrence.   This helps doctors tailor treatment plans specifically for each patient.   By using this test, doctors can better identify who can safely avoid chemotherapy and who might benefit from it, even with potential side effects.   Swipe to find out more.   We are working with DCGEN as part of the ‘2024 Specialized Field Support Program – Global Track’ in collaboration with Seoul Bio Hub.   #SeoulBioHub #Korea #Healthcare #Innovation #Globalisation Kevin Yeo Daehwan Kim Jennifer Kim Heena Kim Wonshik Han Hee-Chul Shin Han-Byoel Lee Young Jun Chai Hongsub Kim

🎙️ The BioHub Episode with Dr. Christopher Haqq is LIVE! 🎙️ In this episode, I sit down with Dr. Chris Haqq, CMO of Elicio Therapeutics, to explore how their cutting-edge AMP platform is revolutionizing cancer immunotherapy by boosting immune responses to target tumors. 🚀 Key highlights include: 💡 How AMP technology enhances immune responses to target tumors. 🏆 Elicio’s strategy to overcome past challenges in cancer vaccines. 💪 Chris’s insights on the future of immuno-oncology and leadership in biotech. This episode is packed with valuable takeaways for anyone in biotech or oncology! 🎧 👉 Catch the full episode via the link in the comments. #TheBioHub #Podcast #Biotech #CancerImmunotherapy #Innovation #ChrisHaqq #ElicioTherapeutics

🚀 Years Of Research At Navaux Begins To Redefine Hepsin's Role In Cancer Genesis 🚀 At Navaux, we’re on a mission to revolutionize cancer detection with our cutting-edge research in non-invasive early detection. We’re thrilled to share a major breakthrough in our work with serine proteases, particularly hepsin. While many have explored hepsin before, our team has uncovered critical differences between full-length hepsin and circulating, activated hepsin—insights that had eluded others. This discovery is a significant step forward in understanding cancer biomarkers and improving early detection methods. We’re proud to announce that we’ve completed epitope mapping and filed patents for our innovative findings related to hepsin. This advancement brings us closer to transforming how cancer is detected and treated, ultimately paving the way for better patient outcomes. A huge thank you to our dedicated team for their hard work and perseverance. We’re excited about the future and the potential impact of our discoveries! 🔬💡 Stay tuned for more updates as we continue to advance the field of cancer research. #CancerResearch #Innovation #EarlyDetection #Hepsin #Navaux #MedicalBreakthrough #Biotech

I and my team have been thinking a lot about the past decade-plus of Immuno-Oncology drug development, which is not surprising since the many of our pre-commercial pre-POC biotech clients are operating in the IO space. As I look back over the many failures of IO agents, both as monotherapy as well as in combination with checkpoint inhibitors, in checkpoint naïve or experienced patients, I have the notion that many of these drugs are not lacking for activity, but rather that they were studied in the wrong way due to lack of sufficient translational insights. Maybe the sequencing was wrong relative to the use of CPI’s or the timing may have been wrong, or the indication or the patient population were suboptimal. Another possibility of course is that we’ve been overly focused on trying to target T cells and too heavily focused on adaptive immunity with too little attention paid to the innate arm of the immune system and the role that it can play in modulating the tumor microenvironment. No doubt it is the effector T cells that provide the ultimate anti-cancer effect for the immune system, but so many other elements go into enabling, facilitating and optimizing that activity. So could modulation of innate immunity be the missing link in potentially providing additional clinical benefit along with checkpoint inhibitors? #immunotherapy #immunooncology #cancer #oncology

🚨 Breaking Boundaries in Cancer Research: The Molecular Jackhammer! 🔬⚡ Researchers at Rice University have made a ground-shaking discovery, developing what they're calling a "molecular jackhammer" to crush cancer cells! This innovative approach uses vibrating molecules to smash the integrity of cancer cell membranes—destroying them with precision. 💥🧬 Using near-infrared light 🌟, the team activates specially designed aminocyanine molecules to vibrate like tiny jackhammers, targeting cancer cells while minimizing harm to healthy tissues. 🛡️ This method could be a game-changer for cancer therapy, offering less invasive, highly targeted treatments. 🎯 Could this be the future of cancer care? I’m excited to see how this new technology could shake up the landscape of cancer treatment! 🌍💪 #CancerResearch #Innovation #Biotech #MolecularMedicine #Oncology #MedicalBreakthroughs #RiceUniversity Read more: https://lnkd.in/ehGAjGvg

✨🧬 How is Next-Generation Sequencing (NGS) transforming precision cancer testing 🧬✨ Read here: https://lnkd.in/dDRbSc7R NGS stands out as a beacon of hope, offering unprecedented accuracy and speed in diagnosing and treating cancer. This breakthrough technology is not just about identifying cancer earlier; it’s about tailoring treatments to the genetic makeup of each patient's cancer, ensuring more effective and less invasive therapeutic strategies. Dara McCreary Discover how NGS is revolutionizing oncology, making targeted therapy a reality, and bringing us closer than ever to turning the tide against cancer. Illumina MGI Thermo Fisher Scientific PacBio #PrecisionMedicine #CancerResearch #NGSSequencing #Oncology #InnovationInHealthcare #dnasequencing #sanger #oxfordnanopore #LIMS #ELN #LabInformatics #Labsoftware #LabInstruments #PrecisionResearch #precisiononcology

🔬 Exciting News in Cancer Research! 🔬 🌟 Firefly Bio: Revolutionizing Cancer Treatment 🌟 Firefly Bio, a cutting-edge biotech company, is making waves in the fight against cancer. They’ve developed a groundbreaking therapy called degrader-antibody conjugates (DACs), combining the best of antibody-drug conjugates (ADCs) with the power of protein degraders. Why DACs Matter? DACs promise to be more selective and potent in delivering their payload to cancer cells, while sparing healthy tissue. Plus, they can target new biology beyond the three mechanisms of action approved in ADCs. Funding and Dream Team Firefly Bio has secured a whopping $94 million in funding, with support from Eli Lilly and other investors. Their dream team includes experts from Versant Ventures, Genentech, Merck, Novartis, and even Nobel laureate Carolyn Bertozzi! Mission: Solid Tumors Firefly Bio’s mission? Tackling solid tumor targets that have faced dose-limiting toxicities. They’ve already selected a lead asset and proven their concept. #CancerResearch #FireflyBio #DACs #Innovation

On World Cancer Research Day, it is important to recognise the profound impact of cancer worldwide. Cancer is the second leading cause of death, accounting for approximately 10 million deaths in 2020. At Engitix, we are committed to driving innovation in cancer research, with a focus on primary and metastatic gastrointestinal tumours. We are harnessing the power of the extracellular matrix (ECM), a key component of the tumour microenvironment and player in tumour progression, which has been often overlooked in drug discovery research. By leveraging Engitix's cutting-edge ECM technology, we are able to better understand disease biology, identify and validate more relevant drug targets and more accurately predict the efficacy of potential therapeutics. #WorldCancerResearchDay #CancerResearch #THEECMcompany #DrugDiscovery 

🎙️ Excited to share a podcast which delves deep into the intricacies of ovarian cancer biomarker testing and pre-analytical phase challenges: https://lnkd.in/gQzqqGb2. You’ll learn how to meet these challenges, including the best- practices for tissue collection and preservation. Joined by eminent experts Assoc. Prof. Martina Murphy and Assoc. Prof. Caterina Marchiò, this podcast also unravels the significance of genetic alterations identification in ovarian cancer. 🔍 Clinical Takeaways: ✅ Adherence to guidelines is crucial for proper sample fixation and DNA integrity preservation. ✅ Effective patient-oncologist communication is pivotal for understanding biomarker significance and the role of comprehensive testing for personalized medicine. ✅ Multidisciplinary collaboration is key for informed decision-making and patient engagement. ✅ Identifying clinical-relevant biomarkers like BRCA1/BRCA2 and HRD status informs personalized treatment in ovarian cancer. Don't miss out on this enriching conversation! Tune in now and stay ahead in the realm of oncology and personalized medicine. #OvarianCancer #BiomarkerTesting #PersonalizedMedicine #Oncology #PodcastSeries